Evidence map›Paper›PMID 15118761›Full record

ArticleCancer gene therapy2004

DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins.

Anthony P Wlazlo, Hongying Deng, Wynetta Giles-Davis, Hildegund C J Ertl

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Immunotherapy for HPV Malignancies.Seminars in radiation oncology · 2021
    Review
  5. Review
  6. Article
  7. Therapeutic HPV DNA vaccines.Immunologic research · 2010
    Review
  8. Immunotherapy for cervical cancer: Research status and clinical potential.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2010
    Review
  9. Perspectives for preventive and therapeutic HPV vaccines.Journal of the Formosan Medical Association = Taiwan yi zhi · 2010
    Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Anthony P WlazloThe Wistar Institute, 3601 Spruce St., Philadelphia, Pennsylvania 19104, USA.
Hongying Deng
Wynetta Giles-Davis
Hildegund C J Ertl
The Wistar Institute · USNational Institutes of Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA vaccines expressing the E6 or E7 oncoproteins of human papilloma virus type 16 (HPV-16) in either their wild-type form or fused to sequences that affect intracellular trafficking were tested for induction of protective immunity against tumor cell challenge in two models based on BALB/c and C57Bl/6 mice. The DNA vaccines to E7 gave uniformly disappointing results, while the DNA vaccine that expressed E6 linked to a viral leader sequence protected BALB/c mice against tumor cell challenge given before or after vaccination. The efficacy of this vaccine could be enhanced by a DNA vector prime/viral vector boost regimen. In contrast, priming of mice with the DNA vaccines to E7 reduced the efficacy of a viral vector expressing the same antigen.

Indexed as

Cancer VaccinesPapillomavirus VaccinesVaccines, DNAAdenoviridaeAnimalsBaculoviridaeCell LineCOS CellsCytokinesDNAGenetic VectorsHumansInterleukin-2MiceMice, Inbred BALB CMice, Inbred C57BLCancer VaccinesCytokinesDNAE6 protein, Human papillomavirus type 16Interleukin-2oncogene protein E7, Human papillomavirus type 16Oncogene Proteins, ViralPapillomavirus E7 ProteinsPapillomavirus VaccinesPeptidesRepressor ProteinsVaccines, DNA

Identifiers

PMID15118761
OpenAlexW2050388991

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.